Deutsche Bank raised the firm’s price target on Cellebrite to $18 from $15 and keeps a Buy rating on the shares. The company reported “solid” Q2 results and increased guidance across the board, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT: